- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
L-lysine escinat® reduces the activity of lysosomal hydrolases, which prevents the breakdown of mucopolysaccharides in the walls of the capillaries and in the connective tissue that surrounds them, and thus normalizes the increased vascular tissue permeability and has anti-exudative (anti-edema) and anesthetic action. The drug increases the tone of blood vessels, has a moderate hypoglycemic effect.
- Post-traumatic and postoperative swelling of soft tissues of various localization.
- Swelling of the brain or spinal cord of traumatic or postoperative origin.
- Disturbances of peripheral venous circulation, accompanied by edema.
Active substance: L-lysine escinate, in terms of 100% substance - 1.0 mg.
Excipients: ethanol (ethyl alcohol) 96% 200.0 mg, propylene glycol 200.0 mg, water for injection to 1 ml.
No customer reviews for the moment.
Dosage and Administration
The drug is administered strictly intravenously slowly in a stream or drip (intra-arterial injection is not allowed!) In a daily dose of 5-10 ml. Recommended intravenous drip. When preparing an infusion solution of L-lysine, Escinate® is diluted in 50-100 ml of 0.9% sodium chloride solution. If necessary, intravenous jet injection of L-lysine Scinat® is diluted in 10-15 ml of 0.9% sodium chloride solution. Without prior dilution, the drug is not used.
Under conditions that threaten the patient's life (traumatic brain injury, postoperative swelling of the brain and spinal cord with signs of swelling, swelling of large sizes due to extensive injuries of soft tissues), the daily dose is increased to 20 ml, divided into 2 doses. The duration of treatment is from 2 to 8 days, depending on the condition of the patient and the effectiveness of therapy.
At the time of taking the drug should refrain from driving and other mechanisms.
In case of individual hypersensitivity to escin in certain patients, the following are possible:
Allergic reactions: skin rash (papular, petechial, erythematous), pruritus, flushing of the face, lips, fever, urticaria, in rare cases - angioedema, anaphylactic shock;
From the central and peripheral nervous system: headache, dizziness, tremor, in a few cases - ataxia, short-term loss of consciousness;
Liver and biliary system: increased transaminase and bilirubin activity;
From the gastrointestinal tract: nausea, in rare cases - vomiting, diarrhea;
Since the cardiovascular system: reduction of blood pressure (hypotension), increased blood pressure (hypertension), tachycardia, pain in the chest;
On the part of the respiratory system: isolated cases - a feeling of lack of air, shortness of breath, bronchial obstruction, dry cough;
Local reactions: burning along the vein when injected, phlebitis, pain in the arm;
Others: general weakness, chills, fever.
If any of the side effects indicated in the instruction are aggravated, or you have noticed any other side effects that are not indicated in the instruction, inform your doctor.
- Hypersensitivity to L-lysine escinate® and / or other components of the drug.
- Severe renal dysfunction.
- Severe abnormal liver function.
- Children's age up to 18 years.
- Breastfeeding period.
The drug should not be used simultaneously with aminoglycosides due to the possibility of increasing their nephrotoxicity. In the case of a recent, prior to the prescription of L-lysine escinate®, long-term anticoagulant therapy, or, if necessary, the simultaneous prescription of L-lysine escinate® and anticoagulants, it is necessary to adjust the dose of the latter under the control of the prothrombin index.
The binding of escin to plasma proteins is hampered by the simultaneous use of cephalosporin-type antibiotics, which may increase the concentration of free escin in the blood at risk of developing side effects of the latter.
Pregnancy and Lactation
Contraindicated in pregnancy and lactation.
In some patients with hepatocholecistitis, when a drug is prescribed, a transient increase in the activity of transaminases and bilirubin (direct fraction) is possible, which do not pose a threat to patients and do not require discontinuation of the drug.
Symptoms: fever, tachycardia, nausea, heartburn, epigastric pain.
Treatment: symptomatic therapy.
- Brand name: L-lysine escinate
- Active ingredient: Escin lysinate
- Dosage form: Concentrate for preparation of solution for intravenous administration of 1 mg / ml.
- Manufacturer: Halychfarm
- Country of Origin: Ukraine